Primary prevention implantable cardioverter–defibrillator treatment: how to identify patients most likely to benefit?

References

• Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 98(21), 2334–2351 (1998).
   PubMed Web of Science ®Google Scholar
• Gillum RF. Sudden coronary death in the United States: 1980–1985. Circulation 79(4), 756–765 (1989).
   PubMedGoogle Scholar
• Mehra R. Global public health problem of sudden cardiac death. J. Electrocardiol. 40(Suppl. 6), S118–S122 (2007).
   Google Scholar
• Priori SG, Aliot E, Blomstrom-Lundqvist C et al. European Society of Cardiology. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur. Heart J. 24(1), 13–15 (2003).
   PubMedGoogle Scholar
• A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. 337(22), 1576–1583 (1997).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter–defibrillator against amiodarone. Circulation 101(11), 1297–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102(7), 748–754 (2000).
   PubMed Web of Science ®Google Scholar
• de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J. Am. Coll. Cardiol. 30(6), 1500–1505 (1997).
   PubMedGoogle Scholar
• Moss AJ, Zareba W, Hall WJ et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346(12), 877–883 (2002).
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N. Engl. J. Med. 352(3), 225–237 (2005).
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 117(21), e350–e408 (2008).
   PubMed Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M et al.; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114(10), e385–e484 (2006).
   PubMed Web of Science ®Google Scholar
• Maisel WH, Moynahan M, Zuckerman BD et al. Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. JAMA 295(16), 1901–1906 (2006).
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Vyas AK, Hall WJ et al.; MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter–defibrillator in patients with ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 51(3), 288–296 (2008).
   PubMed Web of Science ®Google Scholar
• Levy WC, Lee KL, Hellkamp AS et al. Maximizing survival benefit with primary prevention implantable cardioverter–defibrillator therapy in a heart failure population. Circulation 120(10), 835–842 (2009).
   PubMed Web of Science ®Google Scholar
• Borleffs CJ, van Welsenes GH, van Bommel RJ et al. Mortality risk score in primary prevention implantable cardioverter–defibrillator recipients with non-ischaemic or ischaemic heart disease. Eur. Heart J. 31(6), 712–718 (2010).
   PubMedGoogle Scholar
• van Rees JB, Borleffs CJ, van Welsenes GH et al. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter–defibrillator patients with ischaemic heart disease: the FADES risk score. Heart 98(11), 872–877 (2012).
   PubMedGoogle Scholar
• Singh JP, Hall WJ, McNitt S et al.; MADIT-II Investigators. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J. Am. Coll. Cardiol. 46(9), 1712–1720 (2005).
   PubMedGoogle Scholar
• Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter–defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J. Am. Coll. Cardiol. 44(11), 2166–2172 (2004).
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Mark DB. The high cost of implantable defibrillators. Eur. Heart J. 28(4), 388–391 (2007).
   PubMedGoogle Scholar